Clinical Trial Detail

NCT ID NCT02654587
Title Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor (ATALANTE 1)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors OSE Immunotherapeutics

lung non-small cell carcinoma


OSE 2101

Pemetrexed Disodium


Age Groups: adult senior

Additional content available in CKB BOOST